Opaleye Management’s KalVista Pharmaceuticals KALV Stock Holding History

Opaleye Management’s Portfolio KALV Stock Details KALV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-150,000	Closed	-$1.84M	–	56
2023 Q4	$1.84M	Sell	150,000 -350,000	-70%	-$3.18M	0.49%	37
2023 Q3	$4.82M	Sell	500,000 -220,000	-31%	-$2.25M	1.57%	15
2023 Q2	$6.48M	Sell	720,000 -203,200	-22%	-$1.87M	1.55%	15
2023 Q1	$7.26M	Hold	923,200	–	–	2.17%	13
2022 Q4	$6.24M	Buy	+923,200	New	+$4.95M	2.17%	14
2021 Q1	–	Sell	-470,203	Closed	-$8.93M	–	62
2020 Q4	$8.93M	Hold	470,203	–	–	1.17%	24
2020 Q3	$5.86M	Buy	470,203 +8,703	+2%	+$109K	1.15%	32
2020 Q2	$5.58M	Buy	461,500 +236,500	+105%	+$2.51M	1.13%	31
2020 Q1	$1.72M	Buy	+225,000	New	+$3.04M	0.46%	38

Other funds holding KALV

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Opaleye Management's KALV Position: Q1 2024 in Review

Opaleye Management sold out of KalVista Pharmaceuticals (KALV) in Q1 2024, closing a stake of 150,000 shares — an estimated $1.84M sold.

Opaleye Management first reported a position in KALV in Q1 2020 and held it in 9 quarters. The position peaked at $8.93M in Q4 2020. 128 funds tracked by Wall St. Rank hold KALV as of Q1 2024.

Opaleye Management reported no remaining KalVista Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Opaleye Management sold 150,000 KalVista Pharmaceuticals shares in Q1 2024, an estimated $1.84M.
Opaleye Management first reported a position in KalVista Pharmaceuticals in Q1 2020 and held it in 9 quarters.
Opaleye Management's KalVista Pharmaceuticals position peaked at $8.93M in Q4 2020.
128 funds tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q1 2024.

Based on Opaleye Management's 13F filing for Q1 2024, filed 15 May 2024.